Sydney, Australia – Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the launch of Azurion, its next generation image guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast-growing image guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs.
A leader in advanced catheters for diagnosis and therapy, following the acquisition of Volcano in 2015, Philips is now further cementing its position in image guided therapy. Philips’ Azurion image-guided therapy platform for interventional labs is the result of a multi-year, collaborative development program conducted with leading clinicians in the field. This next generation platform enables clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab.
“Philips’ vision is to provide seamlessly integrated solutions that advance minimally invasive procedures by helping physicians to decide, guide, treat and confirm the right therapy for reach patient at the point of care,” said Kevin Barrow, Managing Director, Philips Australia and New Zealand.
Azurion has been designed to address the industry challenges of controlling costs while maintaining their standards of care. The platform is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services.